Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Role of extracellular vesicles as potential diagnostic and/or therapeutic biomarkers in chronic cardiovascular diseases

  • Martín-Ventura, José Luis
  • Roncal Mancho, Carmen
  • Orbe, Josune
  • Blanco-Colio, Luis Miguel
Cardiovascular diseases (CVDs) are the first cause of death worldwide. In recent years, there has been great interest in the analysis of extracellular vesicles (EVs), including exosomes and microparticles, as potential mediators of biological communication between circulating cells/plasma and cells of the vasculature. Besides their activity as biological effectors, EVs have been also investigated as circulating/systemic biomarkers in different acute and chronic CVDs. In this review, the role of EVs as potential diagnostic and prognostic biomarkers in chronic cardiovascular diseases, including atherosclerosis (mainly, peripheral arterial disease, PAD), aortic stenosis (AS) and aortic aneurysms (AAs), will be described. Mechanistically, we will analyze the implication of EVs in pathological processes associated to cardiovascular remodeling, with special emphasis in their role in vascular and valvular calcification. Specifically, we will focus on the participation of EVs in calcium accumulation in the pathological vascular wall and aortic valves, involving the phenotypic change of vascular smooth muscle cells (SMCs) or valvular interstitial cells (IC) to osteoblast-like cells. The knowledge of the implication of EVs in the pathogenic mechanisms of cardiovascular remodeling is still to be completely deciphered but there are promising results supporting their potential translational application to the diagnosis and therapy of different CVDs., This study was funded by the Spanish Ministry of Economy and Competitiveness (PID2019-106814RB-I00), Comunidad Autónoma de Madrid (Complemento II-CM, S2017/BMD-3673), Instituto de Salud Carlos III (ISCiii-FEDER) (IPT17/0019, PI18/01195, PI19/00065 PI19/00128, and RD21/0006/0008) co-funded by European Regional Development Fund “A way to make Europe (ISCiii-FEDER), Spanish Biomedical Research Centre in Cardiovascular Disease (CB16/11/00371 and CB16/11/00333), The Foundation for Applied Medical Research, Universidad de Navarra (Spain) and La Caixa” Banking Foundation (HR17-00247).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

  • Nuñez, Estefania|||0000-0002-0876-1264
  • Fuster, Valentín
  • Gómez-Serrano, María
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Fernández-Alvira, Juan Miguel
  • Martínez-López, Diego
  • Rodríguez, José Manuel
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Calvo, Enrique
  • Alfayate, Alvaro
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Fernández-Friera, Leticia
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Mendiguren, José María
  • Sánchez-Cabo, Fátima|||0000-0003-1881-1664
  • Sanz Salvo, Javier
  • Ordovás, José María
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • García-Ruiz, José Manuel
  • Ibañez, Borja|||0000-0002-5036-254X
  • Lara-Pezzi, Enrique
  • Fernández-Ortiz, Antonio
  • Martín-Ventura, José Luis
  • Vázquez, Jesús|||0000-0003-1461-5092
Background: Imaging of subclinical atherosclerosis improves cardiovascular risk prediction on top of traditional risk factors. However, cardiovascular imaging is not universally available. This work aims to identify circulating proteins that could predict subclinical atherosclerosis. Methods: Hypothesis-free proteomics was used to analyze plasma from 444 subjects from PESA cohort study (222 with extensive atherosclerosis on imaging, and 222 matched controls) at two timepoints (three years apart) for discovery, and from 350 subjects from AWHS cohort study (175 subjects with extensive atherosclerosis on imaging and 175 matched controls) for external validation. A selected three-protein panel was further validated by immunoturbidimetry in the AWHS population and in 2999 subjects from ILERVAS cohort study. Findings: PIGR, IGHA2, APOA, HPT and HEP2 were associated with subclinical atherosclerosis independently from traditional risk factors at both timepoints in the discovery and validation cohorts. Multivariate analysis rendered a potential three-protein biomarker panel, including IGHA2, APOA and HPT. Immunoturbidimetry confirmed the independent associations of these three proteins with subclinical atherosclerosis in AWHS and ILERVAS. A machine-learning model with these three proteins was able to predict subclinical atherosclerosis in ILERVAS (AUC [95%CI]:0.73 [0.70-0.74], p < 1 × 10), and also in the subpopulation of individuals with low cardiovascular risk according to FHS 10-year score (0.71 [0.69-0.73], p < 1 × 10). Interpretation: Plasma levels of IGHA2, APOA and HPT are associated with subclinical atherosclerosis independently of traditional risk factors and offers potential to predict this disease. The panel could improve primary prevention strategies in areas where imaging is not available.